$Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma$

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantle cell lymphoma

Mantle cell lymphoma (MCL) is a distinct histological type of B-cell lymphoma with a poor prognosis. Several agents, such as proteasome inhibitors, immunomodulatory drugs, and inhibitors of B cell lymphoma-2 and Bruton's tyrosine kinase have shown efficacy for relapsed or refractory (r/r) MCL b...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Frontiers of medicine 2020-12, Vol.14 (6), p.811-815
Hauptverfasser:	Li, Ping, Dong, Ningxin, Zeng, Yu, Liu, Jie, Tang, Xiaochen, Wang, Junbang, Zhang, Wenjun, Ye, Shiguang, Zhou, Lili, Chang, Alex Hongsheng, Liang, Aibin
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged anti-CD19 chimeric antigen receptor T cells Antigens Cell- and Tissue-Based Therapy Commentary Humans Immunotherapy, Adoptive long-term follow-up Lymphoma Lymphoma, Mantle-Cell - therapy mantle cell lymphoma Medicine Medicine & Public Health Neoplasm Recurrence, Local Receptors, Chimeric Antigen relapsed or refractory
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!